| Methods |
2‐to 4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 100‐120 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
Benazepril 20 mg: n=77(32 males,45 females); mean age=55.8(8.7) years; baseline sitting SBP=166.8(14.8) mm Hg, DBP=106.7(4.6) mm Hg;
Placebo: n=77(33 males,44 females); mean age=57.2(9.5) years; baseline sitting SBP=166.4(14.1) mm Hg, DBP=106.9(4.7) mm Hg |
| Interventions |
Benazepril 20 mg once daily;
Placebo;
administered at approximately 8 AM |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP reported, endpoint SD not reported, baseline SBP SD reported, imputed baseline SBP SD for SBP SD of change, imputed overall trial mean DBP SD of change; BP data from Table II, p. 1218; Jadad score=3; funding source= Ciba‐Geigy |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
